论文部分内容阅读
目的:探讨依达拉奉联合早期肠内营养对重型颅脑创伤患者肠道黏膜屏障功能和炎性因子的影响。方法:选择兰溪市人民医院2017年1月至2018年12月收治的重型颅脑创伤患者80例，依据随机数字表法分为观察组40例与对照组40例。对照组患者给予早期肠内营养治疗，观察组在对照组基础上结合依达拉奉治疗。两组疗程均为4周。比较两组治疗前后格拉斯哥昏迷指数评分(GCS)、颅内压、神经功能缺损程度(NIHSS)评分、肠道黏膜屏障功能和炎性因子变化，及治疗后3个月预后情况。结果:观察组治疗后GCS评分(12.32±1.02)分，高于对照组的(9.87±1.45)分，而颅内压(169.84±10.19)mmHn 2O、NIHSS评分(10.73±1.98)分，均低于对照组的(203.24±15.69)分和(16.52±3.07)分(n t＝8.740、11.291、10.024，均n P<0.05)。观察组治疗后血清二胺氧化酶活性(DAO)(0.64±0.12)U/L、内毒素(2.54±0.48)U/mL、D-乳酸(3.64±1.09)μg/L，均低于对照组的(1.32±0.30)U/L、(3.64±0.61)U/mL和(5.73±1.18)μg/L(n t＝13.310、8.963、8.229，均n P<0.05)。观察组治疗后血清白细胞介素6(IL-6)(27.39±5.64)pg/L、超敏C反应蛋白(hs-CRP)(10.38±3.24)mg/L、肿瘤坏死因子α(TNF-α)(7.83±1.79)μg/L，均低于对照组的(39.98±9.97)pg/L、(15.64±3.19)mg/L和(13.24±3.21)μg/L(n t＝6.951、7.317、9.310，均n P<0.05)。观察组预后良好率(80.00%)优于对照组(57.00%)(χn 2＝4.713，n P<0.05)。n 结论:依达拉奉联合早期肠内营养对重型颅脑创伤患者治疗效果好，可改善患者肠道黏膜屏障功能，减轻炎性反应及改善预后。“,”Objective:To investigate the effect of edaravone combined with early enteral nutrition on intestinal mucosal barrier function and inflammatory factors in patients with severe craniocerebral trauma.Methods:From January 2017 to December 2018, 80 patients with severe craniocerebral trauma admitted to Lanxi People's Hospital were divided into observation group(40 cases) and control group(40 cases) according to the random digital table method.The control group was given early enteral nutrition treatment, and the observation group was treated with edaravone on the basis of the control group.The course of treatment in both two groups was 4 weeks.Glasgow coma index(GCS), intracranial pressure, NIHSS, intestinal mucosal barrier function and inflammatory factors before and after treatment were compared between the two groups.Results:The GCS score of the observation group[(12.32±1.02)points] was higher than that of the control group[(9.87±1.45)points], while the intracranial pressure[(169.84±10.19)mmHn 2O] and NIHSS score[(10.73±1.98)points]of the observation group were lower than those of the control group [(203.24±15.69)mmHn 2O and (16.52±3.07)points], the differences were statistically significant(n t=8.740, 11.291, 10.024, all n P<0.05). The levels of DAO [(0.64±0.12)U/L], endotoxin [(2.54±0.48)U/mL] and D-lactate [(3.64±1.09)μg/L] in the observation group were lower than those in the control group [(1.32±0.30)U/L, (3.64±0.61)U/mL and (5.73±1.18)μg/L] (n t=13.310, 8.963, 8.229, all n P<0.05). The levels of IL-6[(27.39±5.64)pg/L], hs-CRP[(10.38±3.24)mg/L] and TNF-α[(7.83±1.79)μg/L] in the observation group were lower than those in the control group [(39.98±9.97)pg/L, (15.64±3.19)mg/L and (13.24±3.21)μg/L] (n t=6.951, 7.317, 9.310, all n P<0.05). The good prognosis rate of the observation group(80.00%) was higher than that of the control group(57.00%)(χn 2=4.713, n P<0.05).n Conclusion:Edaravone combined with early enteral nutrition has good effect on the patients with severe craniocerebral trauma.It can improve the intestinal mucosal barrier function, reduce the inflammatory response and improve the prognosis.